Decennale di HIGHLIGHTS in RADIOTERAPIA

Update degli Studi Practice Changing 2024

Undicesima Edizione

In memoria di Renzo Corvò

NEW EVIDENCE AND PRACTICE CHANGING TREATMENTS IN GENITO-URINARY TUMORS (LOCALIZED PROSTATE)

Filippo Alongi

Professor of Radiation Oncology, University of Brescia

Chair of Advanced Radiation Oncology Department IRCCS, Sacro Cuore Don Calabria Cancer Care Center, Negrar-Verona, Italy

ROMA 30-31 gennaio 2025 Starhotels Metropole



DECENNALE di HIGHLIGHTS IN RADIOTERAPIA Update degli Studi Practice Changing 2024 Roma, 30-31 gennaio 2025

NEW EVIDENCE AND PRACTICE CHANGING TREATMENTS IN GENITO-URINARY TUMORS (LOCALIZED PROSTATE)

Filippo Alongi

Professor of Radiation Oncology, University of Brescia

Chair of Advanced Radiation Oncology Department IRCCS, Sacro Cuore Don Calabria Cancer Care Center, Negrar-Verona, Italy







DISCLOSURES & CONFLICTS OF INTERESTS

Speaker Honoraria: •ASTELLAS •ASTRA ZENECA •BOSTON SCIENTIFIC •BRAINLAB •C-RAD •ELEKTA •IPSEN

- •RECORDATI
- •VARIAN
- •TAKEDA

Advisory Board: •ASTRA ZENECA •ASTELLAS •FERRING •IPSEN •JANSEEN •ERGEA

Consultant: •ELEKTA •VARIAN


Research Grant: •ASTELLAS •ASTRA ZENECA •JANSEEN •BRAINLAB





HYPOFRACTIONATION & PROSTATE CANCER:

TECHNOLOGY







HYPOFRACTIONATION & PROSTATE CANCER:


TECHNOLOGY




ADAPTIVE & MOTION MANAGEMENT

Unexpected Movements:

- Patient repositioning
- Peristalsis / passing of gas







AGENDA

- 1. News in radical approach for prostate cancer patients
- 2. News in post-radical setting for prostate cancer patients







AGENDA

1. News in radical approach for prostate cancer patients

2. News in post-radical setting for prostate cancer patients







EVIDENCE & INDICATIONS



6.3.1.3 Summary of evidence and guidelines for the management of low-risk disease*

Summary of evidence	LE
WW or AS is SOC, based on life expectancy.	2a
All active treatment options present a risk of over-treatment.	1a

EAU - EANM - ESTRO -ESUR - ISUP - SIOG Guidelines on

Prostate Cancer

P Conford (Char), D. Tiki (Vice-chair), R. C.N. van den Bergh, E. Briers, Patient Advocate (European Postate Cancer Coalition/Europa UGMO), D. Eberli, G. De Meerleer, M. De Santa, S. Gillessen, A.M. Henry, G.J.L.H. van Leenders, J. Oldenburg, I.M. van Oor, D. E. Oprez-Lager, G. Pousaed, M. Roberta, O. Rouvière, L.G. Schootta, J. Stranne, T. Wiegel Guidelines Associates: T. Van den Bforcek, O. Brunckhorzt, A. Farolf, G. Gandgila, N. Grivas, M. Landas, M. Liew, E. Li.nares Espinos, P.-W. Willemse Guidelines Office: J. Daraugh, E. Smith, N. Schouten



Recommendations	Strength rating
Watchful Waiting	
Manage patients with a life expectancy < ten years by watchful waiting.	Strong
Active surveillance (AS)	
Manage patients with a life expectancy > ten years and low-risk disease by AS.	Strong
Selection of patients	
Patients with cribriform or intraductal histology on biopsy should be excluded from AS.	Strong
Perform magnetic resonance imaging (MRI) before a confirmatory biopsy if no MRI has been performed before the initial biopsy.	Strong
Take both targeted biopsy (of any PI-RADS ≥ 3 lesion) and systematic biopsy if a confirmatory biopsy is performed.	Strong
If MRI is not available, per-protocol confirmatory prostate biopsies should be performed.	Weak



NO MORE LOW RISK PATIENTS WILL BE UP FRONT TREATED ?







Printed by filippo alongi on 5/22/2024 7:24:00 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved.



PRINCIPLES OF RADIATION THERAPY

Table 1: Below are examples of regimens that have shown acceptable efficacy and toxicity. The optimal regimen for an individual patient warrants evaluation of comorbid conditions, voiding symptoms and toxicity of therapy. Additional fractionation schemes may be used as long as sound oncologic principles and appropriate estimate of BED are considered. See <u>PROS-3</u>, <u>PROS-4</u>, <u>PROS-6</u>, <u>PROS-6</u>,


		NCCN Risk Group (✓ indicates an appropriate regimen option if RT is given)					
Regimen	Preferred Dose/Fractionation	Very Low and Low	Favorable Intermediate	Unfavorable Intermediate	High and Very High	Regional N1 ^e	Low Metastatic Burden M1 ^e
EBRT	1			•		•	
Moderate Hypofractionation ^C	3 Gy x 20 fx 2.7 Gy x 26 fx 2.5 Gy x 28 fx	~	~	~	\checkmark	~	
	2.75 Gy x 20 fx						✓
	1.8–2 Gy x 37–45 fx	\checkmark	~	✓	\checkmark	~	
Conventional Fractionation ^C	2.2 Gy x 35 fx + micro-boost ^d to MRI-dominant lesion to up to 95 Gy (fractions up to 2.7 Gy)		\checkmark	\checkmark	\checkmark		
SBRT Ultra- Hypofractionation	9.5 Gy x 4 ix 7.25–8 Gy x 5 fx ^C 6.1 Gy x 7 fx ^C	\checkmark	\checkmark	~	~		
	6 Gy x 6 fx ^C						~
Brachytherapy Mon	otherapy						
LDR Iodine 125 ^C Palladium 103 ^C Cesium 131	145 Gy ^C 125 Gy ^C 115 Gy	\checkmark	\checkmark				
HDR Iridium-192	13.5 Gy x 2 implants 9.5 Gy BID x 2 implants	~	~				
Boost Brachytherap	y or SBRT with EBRT (combined wi	th 1.8 Gy x 25-28 f	x or 2.5 Gy x 15 fx)			
LDR Iodine 125 ^C Palladium 103 Cesium 131	110–115 Gy 90–100 Gy 85 Gy			~	~		
HDR Iridium-192	15 Gy x 1 fx ^C 10.75 Gy x 2 fx			~	\checkmark		
EBRT + SBRT Boost	9.5 Gy x 2 fx for SBRT boost			~	\checkmark		
Frials: NCCN believes	e category 2A unless otherwise indicat that the best management of any patie mprehensive Cancer Network ^e (NCCN [®]). All rights res	ent with cancer is in				/ encouraged.	ootnotes (PRC <u>Continued</u>

Update degli Studi Practice Changing 2024

IGHLIGHTS in RADIOTERAPIA



EVIDENCE & INDICATIONS OF IN FAVOUR OF SBRT IN 5-SESSIONS



- Phase 3 open-label multiple-cohort RCT. In PACE-A, people with LPCa, T1-T2, Gleason≤3+4, PSA≤20ng/mL & suitable for surgery were randomised (1:1) to SBRT or surgery. SBRT dose was 36.25Gy/5 fractions in 1-2 weeks; surgery was laparoscopic or robotically assisted prostatectomy
- From Aug 2012 to Feb 2022, 123 men from 10 UK centres were randomised
- Compared to surgery, pts receiving SBRT had better urinary continence & sexual bother score; clinician reported GI toxicity was low but SBRT pts reported more bowel bother at 2 years

The results suggest that stereotactic body radiotherapy may lead to lower rates of urinary incontinence and sexual dysfunction compared to radical prostatectomy, albeit with a potential increase in bowel dysfunction.



PACE-A CRITICISMS??....





"Can we therefore, on the basis of PACE-A, state the superiority of SBRT as the "best" local treatment for intermediate-risk prostate cancer?"

We do not believe that the present study provides sufficient evidence for such a statement, as many questions and relevant doubts remain, which in our opinion call into question the generalizability of these data

1. **INCONTINENCE:** the rate of 50% pad use at 2 yr after RP recorded here is difficult to understand, substantially higher than results from multiple RP series. The incontinence rates of 25-34% in the ProtecT trial after open RP were already regarded by many high-volume centers as no longer representative of a modern surgical approach.

2. **SEXUAL ACTIVITY:** In the cohort of men who were potent before RP, erectile function was preserved in 74% of men in the NeuroSAFE Group and in 46% of those in the non-Neuro- SAFE group (p < 0.01). Again, such data are strikingly different to the post-RP potency data reported for PACE-A.

3. **RECRUITMENT AND END POINT CHANGING:** Finally, PACE-A did not reach its initial goal of recruiting 234 patients and was closed early after including approximately half of the study population initially planned.



EVIDENCE & INDICATIONS OF IN FAVOUR OF SBRT IN <u>5-SESSIONS</u>



Update degli Studi Practice Changing 2024







The NEW ENGLAND JOURNAL of MEDICINE

Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer

N. van As, C. Griffin, A. Tree, J. Patel, P. Ostler, H. van der Voet, A. Loblaw, W. Chu, D. Ford, S. Tolan, S. Jain, P. Camilleri, K. Kancherla, J. Frew, A. Chan, O. Naismith, J. Armstrong, J. Staffurth, A. Martin, I. Dayes, P. Wells, D. Price, E. Williamson, J. Pugh, G. Manning, S. Brown, S. Burnett, and E. Hall



The PACE trials





CONCLUSIONS: <u>Five-fraction SBRT was non inferior to control radiotherapy</u> <u>with respect to biochemical or clinical failure</u> and may be an efficacious treatment option for patients with low-to-intermediate-risk localized prostate cancer as defined in this trial.



EVIDENCE & INDICATIONS OF IN FAVOUR OF SBRT IN <u>5-SESSIONS</u> RCT: PACE C







Tree, et al. Radioth Oncol suppl. 2024 (ESTRO 2024)



No. of

No. of

natient

Fig. 3.

natient

EVIDENCE & INDICATIONS OF IN FAVOUR OF (SIB-)SBRT IN <u>5-SESSIONS</u> HYPO-FLAME






Fig. 1. .

GHTS in RADIOTERAPIA

Update degli Studi Practice Changing 2024

100 Patients with intermediate-high-risk PCa were enrolled in the phase II hypo-FLAME trial.

- All were treated with 35 Gy in 5 weekly fractions to the whole prostate gland with an integrated boost up to 50 Gy to the multiparametric MRI-defined tumor(s).
- If the dose constraints to the normal tissues would be exceeded, these were prioritised over the focal boost dose.

✓ At 5 years, the prevalence of grade 2 + GU and GI toxicity was 12 % and 4 %, respectively.

✓ The estimated 5-year bDFS was 93 %.


Ultra-hypofractionated focal boost SBRT is associated with encouraging biochemical control up to 5-year follow-up in pts with intermediate and high-risk PCa



EVIDENCE & INDICATIONS OF IN FAVOUR OF SBRT IN 5-SESSIONS

HIGH RISK (PELVIS SBRT) !!!!! SHARP





• Pelvic control was 98.2%, with 5-year BFFS and OS being 86.1% and 89.3%

Conclusion: For high-risk prostate cancer treated with SBRT, prophylactic pelvic nodal RTwith 25Gy/5# achieved near universal regional control

Vedang M , et al Red J 2025 in press

PSA

only

01

Distant

10

Regional

02

04

Local

03

01



EVIDENCE & INDICATIONS OF IN FAVOUR OF (MR GUIDED) SBRT IN <u>5-SESSIONS</u>

RCT: MIRAGE UPDATE




***	*****		
1+1+1	*[*]*]		
2*2*2	*:*:*:		

ASTRO 2024: MRI-Guided versus CT-Guided SBRT for Prostate Cancer: 2-Year Outcomes from the MIRAGE Randomized Clinical Trial

Previously, the MIRAGE trial showed in a randomized trial (156 pts) that margin reduction using MRI guidance has been shown to reduce acute grade 2+ GU and GI following prostate SBRT

PTV Margins of 4 mm (CT-arm) and 2 mm (MRI-arm) were placed around the prostate and proximal seminal vesicles, and this volume received 40 Gy in 5#.

Parameter	CT (n=77)	MRI (n=79)
Age (median, IQR)	71 (67-77)	71 (68-75)
Risk Group		
Imaging N0		
Favorable Intermediate	15 (19%)	14 (18%)
Unfavorable Intermediate	24 (32%)	40 (51%)
High Risk	21 (27%)	15 (19%)
Very High Risk	9 (12%)	5 (6%)
Imaging N+	7 (9%)	5 (6%)
ADT Use	57 (74%)	49 (62%)
Nodal Radiation	19 (25%)	18 (23%)
GTV Boost	22 (29%)	19 (24%)
Rectal Spacer	32 (42%)	37 (47%)
Prior TURP/HOLEP	3 (4%)	5 (6%)
Prostate Size (mL, median, IQR)	41 (33-59)	39 (30-54)
IPSS (median, IQR)	6 (3-11)	7 (4-12.5)



Compared to CBCT -based SBRT, patients receiving MRI-guided SBRT had significantly lower cumulative incidences of grade 2+ GU and GI through two years



NEWS IN FAVOUR OF SBRT IN SINGLE-SESSIONS

ABRUPT



CLINICAL INVESTIGATION

Ablative Radiation Therapy for Unfavorable Prostate Tumors (ABRUPT): Preliminary Analysis of Toxicity and Quality of Life from a Prospective Study

Stefano Arcangeli, MD,⁺¹ Chiara Chissotti, MD,¹ Federica Ferrario, MD,¹ Raffaella Lucchini, MD,¹ Maria Belmonte, MD,¹ Gorgio Purrello, MD,¹ Riccardo Ray Colciago, MD,¹ Elena De Ponti, MSc,^{1,1} Valeria Facenda, MSc,¹ and Denis Panizza, MSc^{1,1}

*Radiation Oncology Department, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy; ¹School of Medicine and Surgery, University of Milan Bicocca, Milan, Italy; and ¹Medical Physics Department, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy

- Thirty patients enrolled in a single arm prospective trial received 24Gy SDRT to the whole prostate with urethra-sparing and organ motion control delivered on a Linac
- Median follow-up was18 months(range,6-31months), with no ≥G3 late side effects observed. G2 late GI and G2 late GU toxicities occurred in 1and 2 patients, respectively

Table 3 Incidences of acute (<3 months) and late (<6 months) genitourinary and gastrointestinal highest-grade treatmentrelated adverse events according to CTCAE v.5.0

	Acute			Late			
Adverse event	Grade 1	Grade 2	Grade ≥3	Grade 1	Grade 2	Grade ≥3	
Genitourinary	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	
Urinary incontinence	-	-	-	-	2 (6.7)	-	
Urinary frequency	1 (3.3)	1 (3.3)	-	4 (13.3)	1 (3.3)	-	
Urinary urgency	5 (16.7)	2 (6.7)	-	6 (20.0)	2 (6.7)	_	
Urinary retention	-	-	-	-	-	-	
Dysuria	2 (6.7)	2 (6.7)	-	4 (13.3)	1 (3.3)	-	
Hematuria	-	-	-	1 (3.3)	-	-	
Any*	6 (20.0)	2 (6.7)	-	8 (26.7)	2 (6.7)	-	
Gastrointestinal	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	
Hematochezia	-	-	<u></u>	-	-	-	
Tenesmus/Proctitis	1 (3.3)	-	-	2 (6.7)	1 (3.3)		
Fecal Incontinence	-	-	-	-	s .	-	
Bowel frequency	-	-	-	-	-	-	
Any*	1 (3.3)	-		2 (6.7)	1 (3.3)	_	

Abbreviations: CTCAE = Common Terminology Criteria for Adverse Events.

* Any genitourinary or gastrointestinal toxic effect indicates the highest-grade adverse event in that domain for all patients. Patients may have experienced more than 1 category of adverse event.

Promising data on the feasibility and safety of 24Gy whole-gland SDRT with urethra-sparing and organ motion control, in association with androgen deprivation therapy and an adequate prophylactic medication, in organ-confined unfavorablePCa



OTHER NEWS IN ADT+RADICAL PROSTATE CONVENTIONAL RT IN HIGH RISK



RCT: GETUG-AFU18



505 patients were included between June 2009 and January 2013

Patients were randomly assigned to dose-escalated RT (80 Gy) or conventional-dose (70 Gy) with 3 years of ADT in both arms.

The bcPFS was significantly improved in the dose-escalated RT arm compared with conventional RT arm (HR = 0.56, [95% CI, 0.40-0.76], p = 0.0005). The 5-year bcPFS was 91.4% (95% CI, 87.0-94.4) and 88.1% (95% CI, 83.2-91.6), and the 7-year bcPFS 88.1% (95% CI, 83.1-91.7) and 79.2% (95% CI, 73.1-84.0) in dose-escalated RT and conventional RT, respectively.

We did observe significant differences in prostate cancer-specific survival (HR = 0.48 [95% CI, 0.27-0.83], p = 0.0090) and overall survival (HR = 0.61 [95% CI, 0.44-0.85], p = 0.0039)

Conclusions:


Dose-escalation RT in combination with long-term ADT is effective and safe, increasing bcPFS rate but also specific survival and overall survival in high-risk prostate cancer patients without increasing long-term toxicity. <u>Clinical trial information: NCT00967863</u>.



OTHER NEWS IN N1 PELVIC DISEASE

RCT: PEACE V - STORM





- ✓ After SBRT, 25% had pelvic nodal relapse compared with 3% in the ENRT arm.
- ✓ Omission of prostate bed radiotherapy trebled the chance of a prostate bed recurrence (14% vs. 5%).
- On the basis of the data presented, ENRT should be considered optimal care for men who wish to maximise their biochemical and relapsefree survival outcomes.



OTHER NEWS IN RADICAL PROSTATE RT


RCT: PARTIQOL





ASTRO 2024: Prostate Advanced Radiation Technologies Investigating Quality of Life (PARTIQoL): Phase III Randomized Clinical Trial of Proton Therapy vs IMRT for Localized Prostate Cancer





Patients treated with RT for localized prostate cancer achieve excellent HRQoL alongside highly effective tumor control.

No significant differences were observed in HRQoL endpoints or cancer control outcomes between the two modalities.

The investigators continue to monitor participants for longer-term follow-up and secondary endpoints.



AGENDA

1. News in radical approach for prostate cancer patients

2. News in post-radical setting for prostate cancer patients







*

EVIDENCE & INDICATIONS OF IN FAVOUR OF ADT AND POST-OP RT

HIGHLIGHTS in RADIOTERAPIA

RCT: RADICALS-HD


Update degli Studi Practice Changing 2024



Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial

Chris C Parker, Howard Kynaston, Adrian D Cook, Noel W Clarke, Charles N Catton, William R Cross, Peter M Petersen, Rajendra A Persad, Cheryl A Pugh, Fred Saad, John Logue, Heather Payne, Lorna C Bower, Chris Brawley, Mary Rauchenberger, Maroie Barkati, David M Bottomley, Klaus Brasso, Hans T Chung, Peter W M Chung, Ruth Conroy, Alison Falconer, Vicky Ford, Chee L Goh, Catherine M Heath, Nicholas D James, Charmaine Kim-Sing, Ravi Kodavatiganti, Shawn C Malone, Stephen L Morris, Abdenour Nabid, Aldrich D Ong, Rakesh Raman, Sree Rodda, Paula Wells, Jane Worlding, Wendy R Parulekar*, Mahesh K B Parmar*, Matthew R Sydes*, on behalf of the RADICALS investigators†

- Randomised controlled trial of ADT duration (short 6 ms vs long 24 ms course) within the RADICALS protocol.
- 1523 patients at 138 centres, median follow-up of 8,9 years
- 10-year metastasis-free survival was 71.9% (95% CI 67.6-75.7) in the short-course ADT group and 78.1% (74.2-81.5) in the long-course ADT group.
- ✓ Compared with adding 6 months of ADT, adding 24 months of ADT improved metastasis-free survival in people receiving postoperative RT.
- ✓ For individuals who can accept the additional duration of adverse effects, long-course ADT should be offered with postoperative radiotherapy.



Parker C et al , The Lancet 2024



PROMISING STUDIES IN FAVOUR OF POST-OP SBRT IN 5-SESSIONS



POPART



- Fifty patients enrolled in a single arm prospective trial received with PSA levels between 0.1-2.0 ng/mL after radical prostatectomy received Linac-based SBRT to the prostate bed in five fractions every other day for a total dose of 32.5 Gy (EQD21.5 = 74.3 Gy)
- Median follow-up was 12 months(range, 3-27 months), with no \geq G2 late side effects observed.
- Late G1 urinary and rectal toxicities occurred in 46 % and 4 % of patients, respectively

Our findings show that post-prostatectomy SBRT did not result in increased toxicity nor a significant decline in QoL measures, thus showing that it can be safely extended to the postoperative setting.

Maximum late toxicity after RT.

	Grade 1	Grade 2	Grade ≥ 3
Late GU toxicity	N (%)	N (%)	N (%)
Hematuria	2 (4 %)	-	-
Urinary incontinence	16 (32 %)	-	-
Urinary tract obstruction	1 (2 %)	-	_
Urinary frequency	3 (6 %)	_	-
Non-infectious Cystitis	1 (2 %)	-	-
Total	23 (46 %)	-	-
Late GI toxicity	N (%)	N (%)	N (%)
Hematochezia	-	-	-
Tenesmus/Proctitis	1 (2 %)	-	-
Fecal Incontinence	-	-	-
Bowel frequency	1 (2 %)	-	-
Total	2 (4 %)	-	_

Table 4

Median and range of patient-reported QoL using EPIC-CP, ICIQ-SF and IIEF 5.

EPIC-CP	Median (range)		
	Baseline	Last follow-up	
Urinary Incontinence	2 (0 – 8)	2 (0 - 8)	
Urinary Irritation/Obstruction	1 (0 – 4)	1 (0 – 5)	
Bowel Symptoms	0 (0 – 5)	0 (0 – 7)	
Sexual Dysfunctions	5 (0 – 12)	5 (0 – 12)	
Hormonal Symptoms	0 (0 – 7)	0 (0 – 6)	
Quality of Life	9 (0 – 19)	10 (1 – 37)	
ICIQ-SF	Median (range)		
	Baseline	Last follow-up	
Urinary Incontinence	4 (0 – 13)	2 (0 – 16)	
IIEF 5	Median (range)		
	Baseline	Last follow-up	
Erectile Function	13 (0 – 25)	10 (0 – 25)	

EPIC-CP: Expanded Prostate Cancer Index Composite for Clinical Practice; ICIQ-SF: International Consultation on Incontinence Questionnaire Short Form; IIEF 5: International Index of Erectile Function Questionnaire.

6/50 relapses @12 months...

Ferrario F et al, CTRO 2024

Decennale di HIGHLIGHTS in RADIOTERAPIA

Update degli Studi Practice Changing 2024

GRAZIE!!!!!!!!!!

ROMA 30-31 GENNAIO 2025